Before taking this medicine

LIBTAYO may cause severe immune-mediated reactions, infusion-related reactions, and embryo-fetal toxicity, requiring close monitoring and possible discontinuation in certain cases.

Precautions for LIBTAYO Use

LIBTAYO has the potential to cause severe immune-mediated adverse reactions, which can affect multiple organ systems, including the lungs (pneumonitis), colon (colitis), liver (hepatitis), and endocrine glands. These reactions require close monitoring and may necessitate withholding or permanently discontinuing treatment, as well as administration of corticosteroids for management. Infusion-related reactions are also common and should be addressed by adjusting the infusion rate or discontinuing the drug. Additionally, LIBTAYO can cause fetal harm and should not be used during pregnancy, with effective contraception recommended for women of reproductive potential. Further precautions related to specific populations are not specified in the description.

LIBTAYO(Lebrikizumab)
LIBTAYO is indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved